MIRXES-B (02629) to Collaborate with XTALPI on AI-Powered Innovative "Diagnosis-Treatment Integration" Research and Industrialization Platform

Stock News12-05

MIRXES-B (02629) announced that it has recently entered into a memorandum of understanding (MOU) with XTALPI Holdings Limited (XTALPI). Under the agreement, the two parties will combine MIRXES-B's core strengths in genomics technology and its extensive Asian-centric disease database with XTALPI's leading AI and robotics-driven drug discovery and research platform. The collaboration aims to establish an AI-powered, innovative "diagnosis-treatment integration" research and industrialization platform focused on early detection and intervention for cancers prevalent in Asia, particularly gastrointestinal cancers.

The MOU, effective upon signing, will remain valid for two years. This partnership aligns with both companies' long-term goals of advancing early detection and intervention to promote healthier lives. It also marks MIRXES-B's strategic expansion from early detection into early intervention and precision medicine.

By leveraging their complementary strengths—MIRXES-B's high-quality cancer biomarker data, diagnostic resources, and operational advantages in the Asia-Pacific region, alongside XTALPI's AI-driven biopharmaceutical R&D platform, drug development expertise, and big data capabilities—the collaboration seeks to jointly develop and industrialize AI-powered, innovative early diagnosis and treatment solutions for high-incidence cancers in Asia, particularly gastrointestinal cancers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135315158?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135315158","market":"nz","top_or_hot":-1,"title":"MIRXES-B (02629) to Collaborate with XTALPI on AI-Powered Innovative \"Diagnosis-Treatment Integration\" Research and Industrialization Platform","media":"Stock News","content":"<p>MIRXES-B (02629) announced that it has recently entered into a memorandum of understanding (MOU) with XTALPI Holdings Limited (XTALPI). Under the agreement, the two parties will combine MIRXES-B's core strengths in genomics technology and its extensive Asian-centric disease database with XTALPI's leading AI and robotics-driven drug discovery and research platform. The collaboration aims to establish an AI-powered, innovative \"diagnosis-treatment integration\" research and industrialization platform focused on early detection and intervention for cancers prevalent in Asia, particularly gastrointestinal cancers.</p>\n<p>The MOU, effective upon signing, will remain valid for two years. This partnership aligns with both companies' long-term goals of advancing early detection and intervention to promote healthier lives. It also marks MIRXES-B's strategic expansion from early detection into early intervention and precision medicine.</p>\n<p>By leveraging their complementary strengths—MIRXES-B's high-quality cancer biomarker data, diagnostic resources, and operational advantages in the Asia-Pacific region, alongside XTALPI's AI-driven biopharmaceutical R&D platform, drug development expertise, and big data capabilities—the collaboration seeks to jointly develop and industrialize AI-powered, innovative early diagnosis and treatment solutions for high-incidence cancers in Asia, particularly gastrointestinal cancers.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MIRXES-B (02629) to Collaborate with XTALPI on AI-Powered Innovative \"Diagnosis-Treatment Integration\" Research and Industrialization Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMIRXES-B (02629) to Collaborate with XTALPI on AI-Powered Innovative \"Diagnosis-Treatment Integration\" Research and Industrialization Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-05 19:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MIRXES-B (02629) announced that it has recently entered into a memorandum of understanding (MOU) with XTALPI Holdings Limited (XTALPI). Under the agreement, the two parties will combine MIRXES-B's core strengths in genomics technology and its extensive Asian-centric disease database with XTALPI's leading AI and robotics-driven drug discovery and research platform. The collaboration aims to establish an AI-powered, innovative \"diagnosis-treatment integration\" research and industrialization platform focused on early detection and intervention for cancers prevalent in Asia, particularly gastrointestinal cancers.</p>\n<p>The MOU, effective upon signing, will remain valid for two years. This partnership aligns with both companies' long-term goals of advancing early detection and intervention to promote healthier lives. It also marks MIRXES-B's strategic expansion from early detection into early intervention and precision medicine.</p>\n<p>By leveraging their complementary strengths—MIRXES-B's high-quality cancer biomarker data, diagnostic resources, and operational advantages in the Asia-Pacific region, alongside XTALPI's AI-driven biopharmaceutical R&D platform, drug development expertise, and big data capabilities—the collaboration seeks to jointly develop and industrialize AI-powered, innovative early diagnosis and treatment solutions for high-incidence cancers in Asia, particularly gastrointestinal cancers.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1135315158","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135315158","pubTimestamp":1764933148,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MIRXES-B (02629) announced that it has recently entered into a memorandum of understanding (MOU) with XTALPI Holdings Limited (XTALPI). Under the agreement, the two parties will combine MIRXES-B's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02228":"晶泰控股","02629":"MIRXES-B","BK1617":"AI医疗","BK1141":"生命科学工具和服务"},"translate_title":"MIRXES-B(02629)将与XTALPI合作开发人工智能驱动的创新“诊疗一体化”研究和产业化平台","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":1,"02629":1},"content_text":"MIRXES-B (02629) announced that it has recently entered into a memorandum of understanding (MOU) with XTALPI Holdings Limited (XTALPI). Under the agreement, the two parties will combine MIRXES-B's core strengths in genomics technology and its extensive Asian-centric disease database with XTALPI's leading AI and robotics-driven drug discovery and research platform. The collaboration aims to establish an AI-powered, innovative \"diagnosis-treatment integration\" research and industrialization platform focused on early detection and intervention for cancers prevalent in Asia, particularly gastrointestinal cancers.\nThe MOU, effective upon signing, will remain valid for two years. This partnership aligns with both companies' long-term goals of advancing early detection and intervention to promote healthier lives. It also marks MIRXES-B's strategic expansion from early detection into early intervention and precision medicine.\nBy leveraging their complementary strengths—MIRXES-B's high-quality cancer biomarker data, diagnostic resources, and operational advantages in the Asia-Pacific region, alongside XTALPI's AI-driven biopharmaceutical R&D platform, drug development expertise, and big data capabilities—the collaboration seeks to jointly develop and industrialize AI-powered, innovative early diagnosis and treatment solutions for high-incidence cancers in Asia, particularly gastrointestinal cancers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135315158","isCrawlerRequest":true}